PLI Scheme: Approvals accorded for Promotion of APIs

All the 215 applications received for the 36 products spread across the 4 Target Segments were considered and appraised

Govt DoP

Last Updated on June 1, 2021 by The Health Master

The Department of Pharmaceuticals, with an objective to attain self-reliance and reduce import dependence in critical Bulk Drugs – Key Starting Materials (KSMs)/ Drug Intermediates and Active Pharmaceutical Ingredients (APIs), had launched a Production Linked Incentive (PLI) Scheme.

This scheme is for promotion of their domestic manufacturing by setting up greenfield plants with minimum domestic value addition in four different Target Segments (In Two Fermentation based – at least 90% and in Two Chemical Synthesis based – at least 70% ) with a total outlay of Rs.6,940 cr. for the period 2020-21 to 2029-30.

Also read more articles on PLI Scheme, click here

Pharma Factory
Picture: Pixabay

All the 215 applications received for the 36 products spread across the 4 Target Segments were considered and appraised as per the decided evaluation and selection criteria by the Empowered Committee in its various meetings and selected participants duly informed and Press Notes issued with approval of the Competent Authority.

Now, waitlisted applicants who are otherwise eligible have been approved against slots vacated by withdrawal by companies, which had earlier been granted approvals.

The applications of the companies kept in ‘Wait List’, which have committed minimum/more than the minimum proposed annual production capacities and fulfil the prescribed criteria have been approved, as under:

Sr. No.Eligible ProductName of Participant Company which has withdrawnName of Participant kept in Waitlist approved
Target Segment III – Chemical Synthesis Based KSMs/Drug Intermediates
1.1,1 Cyclohexane Diacetic Acid (CDA)M/s Saraca Laboratories LimitedM/s Solara Active Pharma Science Limited
Target Segment IV – Other Chemical Synthesis Based KSMs/Drug Intermediates and APIs
2.MeropenemM/s Anasia Lab Private LimitedM/s Rajasthan Antibiotics Limited
3.RitonavirM/s Surya Remedies Pvt. Ltd.M/s Dhatri Lab Private Limited
4.LevofloxacinM/s Surya Life Science LimitedM/s Vital Laboratories Private Limited

With this, a total of 46 applications with Committed Investment of Rs.5,355.44 crore and Expected Employment Generation of about 11,210have been approved by the Government so far under the PLI Scheme for Bulk Drugs.

Setting up of these plants will make the country self-reliant to a large extent in respect of these Bulk drugs. The disbursal of production linked incentive by the Government over the six years period would be up to a maximum of about Rs.6,000 cr.

Zydus Cadila plans to test its C-19 vaccine for 5-12 age…

Black fungus treatment: IIT is ready for tech transfer of oral…

Take care of your Air, Don’t share it

Zydus Cadila gets USFDA nod for Fluphenazine HCL Tablets

NITI Aayog + Piramal to invest Rs 100 crores towards C-19…

HC quashes petition for selling Schedule H drug Sildenafil without license

YouTube Icon

Enter your email address:

Delivered by FeedBurner